Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment

E. Cabrera-Rode, P. Perich, O. Diaz-Horta, C. Tiberti, G. Molina, C. Arranz, J.M. Martin, M. Licea, A.D. De Leiva, M. Puig-Domingo, U. Dimario

Research output: Contribution to journalArticleResearch

15 Citations (Scopus)
Original languageEnglish
Pages (from-to)469-474
JournalAutoimmunity
Publication statusPublished - 1 Jan 2002

Cite this

Cabrera-Rode, E., Perich, P., Diaz-Horta, O., Tiberti, C., Molina, G., Arranz, C., Martin, J. M., Licea, M., De Leiva, A. D., Puig-Domingo, M., & Dimario, U. (2002). Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity, 469-474.